Biogen Idec International Neuroscience GmbH and University of Zurich File Patent Application for Anti-alpha Synuclein Binding Molecules
The abstract of the patent published by the Controller General of Patents, Designs & Trade Marks states: "Provided is anti-human a synuclein specific binding molecules e.g. antibodies or antiben binding fragments variants or derivatives thereof as methods related thereto.
Uloženo v:
| Vydáno v: | Indian Patents News |
|---|---|
| Médium: | Newsletter |
| Jazyk: | angličtina |
| Vydáno: |
New Delhi
Athena Information Solutions Pvt. Ltd
17.05.2016
|
| Témata: | |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | The abstract of the patent published by the Controller General of Patents, Designs & Trade Marks states: "Provided is anti-human a synuclein specific binding molecules e.g. antibodies or antiben binding fragments variants or derivatives thereof as methods related thereto. |
|---|